A detailed history of Reynders Mc Veigh Capital Management, LLC transactions in Moderna, Inc. stock. As of the latest transaction made, Reynders Mc Veigh Capital Management, LLC holds 8,903 shares of MRNA stock, worth $328,075. This represents 0.03% of its overall portfolio holdings.

Number of Shares
8,903
Previous 13,670 34.87%
Holding current value
$328,075
Previous $1.62 Million 63.34%
% of portfolio
0.03%
Previous 0.09%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$63.64 - $125.14 $303,371 - $596,542
-4,767 Reduced 34.87%
8,903 $595,000
Q2 2024

Aug 13, 2024

BUY
$101.21 - $166.61 $62,547 - $102,964
618 Added 4.73%
13,670 $1.62 Million
Q1 2024

May 07, 2024

BUY
$85.37 - $115.44 $1.11 Million - $1.51 Million
13,052 New
13,052 $1.39 Million
Q4 2023

Feb 07, 2024

BUY
$69.51 - $104.43 $249,401 - $374,694
3,588 Added 34.58%
13,963 $1.39 Million
Q3 2023

Nov 09, 2023

SELL
$96.41 - $126.61 $172,188 - $226,125
-1,786 Reduced 14.69%
10,375 $1.07 Million
Q2 2023

Aug 09, 2023

SELL
$118.5 - $160.53 $214,129 - $290,077
-1,807 Reduced 12.94%
12,161 $1.48 Million
Q1 2023

May 03, 2023

SELL
$135.66 - $197.02 $135,660 - $197,020
-1,000 Reduced 6.68%
13,968 $2.15 Million
Q4 2022

Feb 10, 2023

SELL
$118.38 - $210.04 $212,136 - $376,391
-1,792 Reduced 10.69%
14,968 $2.69 Million
Q3 2022

Nov 08, 2022

BUY
$118.07 - $194.18 $272,859 - $448,749
2,311 Added 15.99%
16,760 $1.98 Million
Q2 2022

Aug 05, 2022

BUY
$117.13 - $176.59 $41,112 - $61,983
351 Added 2.49%
14,449 $2.06 Million
Q1 2022

May 11, 2022

BUY
$126.46 - $235.05 $1.17 Million - $2.18 Million
9,258 Added 191.28%
14,098 $2.43 Million
Q4 2021

Feb 11, 2022

BUY
$225.82 - $368.51 $1.09 Million - $1.78 Million
4,840 New
4,840 $1.23 Million

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $14.4B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Reynders Mc Veigh Capital Management, LLC Portfolio

Follow Reynders Mc Veigh Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Reynders Mc Veigh Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Reynders Mc Veigh Capital Management, LLC with notifications on news.